Scintigraphic imaging of pituitary adenomas: An in vivo evaluation of somatostatin receptors

Journal of Endocrinological Investigation

Volumn 21, Issue 8, 1998, Pages 512-519

  Oppizzi, G ^a,b   Cozzi, R ^a   Dallabonzana, D ^a   Orlandi, P ^a   Benini, Z ^a   Petroncini, M ^a   Attanasio, R ^a   Milella, M ^b   Banfi, G ^b   Possa, M ^b  

^a Divisione di Ematologia   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Acromegaly; Imaging; Octreoscan; Octreotide; Pituitary adenomas

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR;

ACROMEGALY; ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; MALE; SCINTIGRAPHY; TUMOR GROWTH;

EID: 14444280390     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347337     Document Type: Article

References (27)

1. Krenning E.P., Bakker W.H., Breeman W.A.P., Koper J.W, Kooji P.P.M., Ausema L., Lameris J.S., Lamberts S.W.J. Localization of endocrine related tumours with radioiodinated analogue of somatostatin. Lancet I: 242, 1989.
2. Lamberts S.W.J., Bakker W.H., Reubi J.C., Krenning E.P. Somatostatin receptor imaging in the localization of endocrine tumours. N. Engl. J. Med. 323: 1246, 1990.
3. Ikuyama S., Nawata H., Kato K., Ibayashi H., Nakagaki H. Specific somatostatin receptors on human pituitary adenoma cell membranes. J. Clin. Endocrinol. Metab. 61: 666, 1985.
4. Reubi J.C., Heitz P.U., Landolt A.M. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J. Clin. Endocrinol. Metab. 65: 65, 1987.
5. Greenman Y., Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J. Clin. Endocrinol. Metab. 79: 724, 1994.
6. Lamberts S.W.J. Sandostatin in the treatment of acromegaly. Springer-Verlag, New York, 1988, p. 1.
7. Chiodini P.G., Cozzi R., Dallabonzana D., Oppizzi G., Verde G., Petroncini M., Liuzzi A., Boccardi E., Lancranjan I. Medical treatment of acromegaly - Dopaminergic agonists and long-acting somatostatin. In: Muller E.E., Cocchi D., Locatelli V., (Eds.), Advances in growth hormone and growth factor research. Pythagora Press; Roma-Milano Berlin-Heidelberg: Springer-Verlag; 1989, p. 423.
8. Mundler O., Duet M., Chanson P., Rohmer Y., Ajzenberg C., Warnet A. Preliminary results with somatostatin receptors imaging in pituitary adenoma. 3rd Int. Pituitary Congress, Marina del Rey, CA, USA, 1993, Abst MA-43.
9. Faglia G., Bazzoni N., Spada A., Arosio M., Ambrosi B., Spinelli F., Sara R., Bonino C., Lunghi F. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin (123-I SDZ 204-090). J. Clin. Endocrinol. Metab. 73: 850, 1991.
10. Ur E., Mather S.J., Bomanji J., Ellison D., Britton K.E. Grossman A.B., Wass J.A.H., Besser G.M. Pituitary imaging using a labelled somatostatin analogue in acromegaly. Clin. Endocrinol. (Oxf.) 36: 147, 1992.
11. Plockinger U., Reichel M., Fett U., Saeger W., Quabbe H.J. Preoperative octreotide treatment of growth hormone secreting and clinically non-functioning pituitary macroadenomas: effects on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J. Clin. Endocrinol. Metab. 79: 1416, 1994.
12. Colao A.M., Ferone D., Lastoria S., Marzullo P., Cerbone G., Di Sarno A, Longobardi S., Merola B., Salvatore M., Lombardi G. Prediction of efficacy of octreotide therapy in patients with acromegaly. J. Clin. Endocrinol. Metab. 81: 2356, 1996.
13. Ikuyama S., Nawata H., Kato K.I., Ibayashi H., Nakagaki H. Plasma growth hormone responses to somatostatin (SS) and SS receptors in pituitary adenomas in acromegalic patients. J. Clin. Endocrinol. Metab. 62: 729, 1986.
14. Reubi J.C., Landolt A.M. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J. Clin. Endocrinol. Metab. 68: 844, 1989.
15. Borson-Chazot F., Houzard C., Ajzenberg C., Nocaudiet M., Duet M., Mundler O., Marchandise X., Epelbaum J., Gomez de Algaza M., Schaefer J., Meyerhof W., Sassolas G., Warnet A. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. Clin. Endocrinol. (Oxf.) 47: 589, 1997.
16. Oppizzi G., Dallabonzana D., Cozzi R. "Non secreting" pituitary tumors: a morphofunctional study. 3rd Int. Pituitary Congress, Marina del Rey, CA, USA, Abst TA-6, 1993.
17. De Bruin T.W.A., Kwekkeboom D.J., Van't Verlaat J.W.I. Clinically non functioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J. Clin. Endocrinol. Metab. 75: 1310, 1992.
18. Warnet A., Timsit J., Chanson P. The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas. J. Neurosurg. 71: 687, 1989.
19. Warnet A., Harris A., Renard E., Martin D., James-Deidier A., Chaumet-Riffaud P. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin secreting pituitary adenomas. Neurosurgery 41: 786, 1997
20. Liuzzi A., Dallabonzana D., Oppizzi G.I. Is there a real medical treatment for "non-secreting" pituitary adenomas? In: Faglia G., Beck-Peccoz P., Ambrosi B., Travaglini P., Spada A. (Eds.), Pituitary adenomas: new trends in basic and clinical research. Excerpta Medica, Amsterdam, 1991, p 383.
21. Lamberts S.W.J., Uitterlinden P., Verschoor L., Van Dongen K.J., Del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N. Engl. J. Med. 313: 1576, 1985.
22. Chiodini P.G., Cozzi R., Dallabonzana D., Oppizzi G., Liuzzi A. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J. Clin. Endocrinol. Metab. 64: 447, 1987.
23. Barkan A.L., Kelch R.P., Hopwood N.J., Beitins I.Z. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995. J. Clin. Endocrinol. Metab. 66: 16, 1988.
24. Dorr U., Wurm K., Horing E., Guzman G., Rath U., Bihl H. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs. In: Somatostatin receptor imaging. 1st German Meeting, Stuttgart, Germany. Horm. Metab. Res. Suppl. no 27: 36, 1992.
25. Klibanski A., Bikkal H.A., Alexander J.M., Hsu D.W., Swearingen B., Zervas N.T. Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro. J. Clin. Endocrinol. Metab. 73: 1248, 1991.
26. Spada A,. Reza-Elahi F., Lania A., Gil-Del Alamo P., Bassetti M., Faglia G. Hypothalamic peptides modulate cytosolic free Ca2+-levels and adenylyl cyclase activity in human non-functioning pituitary adenomas. J. Clin. Endocrinol. Metab. 73: 913, 1991.
27. Kwekkeboom D.J., Krenning E.P., Lamberts S.W.J. In vitro studies in clinically non functioning pituitary adenomas. J. Endocrinol. Invest. 14 (Suppl 1): 17 (abstract), 1991.